share_log

HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target

Benzinga ·  Sep 14, 2023 06:08

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment